Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Allovir, Inc. | Director | Common Stock | 252K | $2.54M | $10.08 | Mar 18, 2025 | Direct |
Allovir, Inc. | Director | Common Stock | 101K | $1.02M | $10.08 | Mar 18, 2025 | Indirect |
Kalaris Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 18K | Apr 10, 2025 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KLRS | Kalaris Therapeutics, Inc. | Apr 10, 2025 | 1 | $0 | 4 | Apr 11, 2025 | Director |
KLRS | Kalaris Therapeutics, Inc. | Mar 18, 2025 | 3 | $0 | 4 | Mar 18, 2025 | Director |
KLRS | Kalaris Therapeutics, Inc. | Mar 18, 2025 | 0 | $0 | 3 | Mar 18, 2025 | Director |